Immunoglobulin A

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Retrieved on: 
Monday, February 5, 2024
SARS-CoV-2, COVID-19, SAN, Norovirus, Volatile organic compound, Vaxart, Animal, Disease, Immunoglobulin G, Vaccination, Infection, Immunoglobulin A, VOC, Serum, Development, Immunization, Vaccine

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s. The data, which were previously presented at the International Congress of Mucosal Immunology 2022, are reported in the current issue of Vaccines.

Key Points: 
  • “The data published in Vaccines support the potential of our vaccine platform to stimulate potent mucosal cross-reactive IgA responses to multiple VOCs and reduce viral transmission.
  • All three vaccines induced neutralizing antibodies in both the peripheral and mucosal compartments, which was enhanced with a boost immunization.
  • Viral replication and infectious particle shedding were significantly reduced in immunized animals after challenge with beta variant SARS-CoV-2.
  • Vaxart believes these data support the potential for its vaccines to enhance mucosal responses and reduce community transmission, in addition to preventing severe disease.

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Retrieved on: 
Thursday, January 25, 2024
Patient, Pharma, Therapy, IgA nephropathy, Kidney failure, SAN, Kidney disease, Medication, Immunoglobulin A, PMDA, Pharmaceutical industry

Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.

Key Points: 
  • Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.
  • “We’re pleased to partner with Renalys, a company led by distinguished renal experts with a strong track record of launching kidney disease treatments,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
  • As part of the collaboration, Travere has obtained a minority equity stake in Renalys and will be eligible to receive tiered royalties on net sales of sparsentan in Japan, South Korea, Taiwan, and the specified Southeast Asian nations.
  • “Travere is a long-known leader in rare kidney disease, and we are proud to collaborate with this team.”

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Retrieved on: 
Thursday, January 25, 2024
PP, Nephrology, Patient, Therapy, Stanford University Medical Center, OLE, PLOS, UPCR, Safety, Hematuria, Disease, Immunoglobulin A, E pluribus unum, EGFR, Pharmaceutical industry

BRISBANE, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN.

Key Points: 
  • In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN.
  • “Data from the OLE show the consistent and sustained reductions of Gd-lgA1, hematuria, and UPCR, as well as the stability of eGFR over 72 weeks in participants with IgAN.
  • “We are thrilled to present this package of positive new data from the OLE of the Phase 2b ORIGIN clinical trial during our R&D Day, which will be held today in New York.
  • The R&D Day presentation, which includes the OLE 72-Week data slides and commentary, will be available on the Company’s website at the Investor Calendar .

Havas Health & You Appoints Afshan Rizvi Hussain as Global Rare Disease Lead

Retrieved on: 
Thursday, January 25, 2024
Avalere Health, IgA nephropathy, HH, Knowledge, CHIEF, Mentorship, Disease, Immunoglobulin A, Health literacy, Growth, Management

NEW YORK, Jan. 25, 2024 /PRNewswire/ - Havas Health & You (HH&Y), the premier healthcare marketing and communications agency, announced today that Afshan Rizvi Hussain has been appointed Managing Director, Global Rare Disease Lead, for the network.

Key Points: 
  • NEW YORK, Jan. 25, 2024 /PRNewswire/ - Havas Health & You (HH&Y), the premier healthcare marketing and communications agency, announced today that Afshan Rizvi Hussain has been appointed Managing Director, Global Rare Disease Lead, for the network.
  • In this newly created role, Afshan will drive the Havas Health & You approach to deepen connections with rare disease communities and engage with our network clients to optimize rare disease commercialization efforts.
  • As a leader in the specialized rare disease sector, Havas affirms with this appointment their commitment to continued growth and innovation.
  • "Afshan has dedicated her career to developing a very robust understanding of rare disease communities and shining a light on underrepresented communities," said Daniel Rubin, Group President North America,  Havas Health & You.

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

Retrieved on: 
Monday, January 8, 2024
Therapy, IgA nephropathy, Patient, University, EGFR, Immunoglobulin A, FRCP, Stanford University Medical Center, Proteinuria, FACP

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced it will host an in-person R&D day featuring Richard Lafayette, M.D., FACP, from Stanford University Medical Center, who will join company management to present Phase 2b eGFR and proteinuria data from week 72 of the ORIGIN Phase 2b clinical trial of atacicept for the treatment of IgA nephropathy (IgAN), and Jonathan Barratt, Ph.D., FRCP, from the University of Leicester for a discussion of the results, on January 25, 2024.

Key Points: 
  • BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced it will host an in-person R&D day featuring Richard Lafayette, M.D., FACP, from Stanford University Medical Center, who will join company management to present Phase 2b eGFR and proteinuria data from week 72 of the ORIGIN Phase 2b clinical trial of atacicept for the treatment of IgA nephropathy (IgAN), and Jonathan Barratt, Ph.D., FRCP, from the University of Leicester for a discussion of the results, on January 25, 2024.
  • To register, click here.

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Retrieved on: 
Monday, January 8, 2024
AMAG Pharmaceuticals, Vaccine, Hospital, Immunoglobulin A, Nephrology, Amgen, Biotechnology, AstraZeneca, Drug development, Allergy, IgA nephropathy, MAA, MedImmune, Darbepoetin alfa, Johns Hopkins University, NDA, Medical microbiology, California State University, Therapy, GSK, Stanford University Medical Center, Peanut allergy, Regulatory affairs, Kidney, SVP, Patient, Hematology, Iron(II,III) oxide, Pharmaceutical industry

The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.

Key Points: 
  • The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.
  • ; and William D. Turner as Chief Development Officer, effective immediately.
  • Rob and Bill each have successfully guided multiple therapies through late clinical development, regulatory approval and commercial launch.
  • This is a key moment for Vera as we continue to advance the strategy for our late-stage clinical program,” said Marshall Fordyce, M.D., Chief Executive Officer of Vera Therapeutics.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on: 
Sunday, January 7, 2024
NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points: 
  • STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
  • Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
  • Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
  • "We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on: 
Sunday, January 7, 2024
NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points: 
  • STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
  • Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
  • Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
  • "We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.